In today’s session Allergan plc Ordinary Shares (AGN) recorded an unusually high (897) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious AGN decrease. With 897 contracts traded and 18664 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: AGN161216P00220000 closed last at: $28.7 or 10.3% down. About 1.76M shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 14.51% since April 25, 2016 and is downtrending. It has underperformed by 20.53% the S&P500.
Analysts await Allergan plc Ordinary Shares (NYSE:AGN) to report earnings on February, 27. They expect $3.74 earnings per share, up 9.68% or $0.33 from last year’s $3.41 per share. AGN’s profit will be $1.41B for 12.79 P/E if the $3.74 EPS becomes a reality. After $3.32 actual earnings per share reported by Allergan plc Ordinary Shares for the previous quarter, Wall Street now forecasts 12.65% EPS growth.
Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage
Out of 18 analysts covering Allergan Inc. (NYSE:AGN), 14 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 78% are positive. Allergan Inc. has been the topic of 46 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Deutsche Bank on Friday, August 7. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 3 report. Piper Jaffray downgraded it to “Neutral” rating and $238 target price in Monday, April 18 report. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, July 28. Deutsche Bank maintained Allergan plc Ordinary Shares (NYSE:AGN) rating on Friday, August 7. Deutsche Bank has “Buy” rating and $350.0 price target. The firm has “Buy” rating by Mizuho given on Friday, October 9. Mizuho maintained Allergan plc Ordinary Shares (NYSE:AGN) on Tuesday, October 11 with “Buy” rating. As per Friday, November 13, the company rating was maintained by Mizuho. Guggenheim initiated the shares of AGN in a report on Monday, April 18 with “Neutral” rating. Mizuho maintained the stock with “Neutral” rating in Friday, August 5 report.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 4 in Q2 2016. Its up 3.54, from 0.46 in 2016Q1. The ratio is positive, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Grassi Investment Mngmt last reported 0.22% of its portfolio in the stock. Bartlett And Lc has invested 0.01% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Mitchell Mcleod Pugh Williams Inc has invested 0.83% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Gemmer Asset Mgmt Lc holds 127 shares or 0.02% of its portfolio. Connors Investor Ser has 0.04% invested in the company for 1,000 shares. Armstrong Henry H accumulated 3,690 shares or 0.17% of the stock. American Rech And accumulated 0% or 33 shares. Dowling Yahnke reported 2,145 shares or 0.06% of all its holdings. Mengis Mngmt has invested 1.27% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Moreover, Marshwinds Advisory Com has 0.1% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 927 shares. Frontier Invest Management last reported 32,758 shares in the company. Chartist Ca reported 1,844 shares or 0% of all its holdings.
AGN Company Profile
Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States.
More recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016. Also Investorplace.com published the news titled: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. Valuewalk.com‘s news article titled: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” with publication date: April 05, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.